Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Accumulated Expenses (2020 - 2026)

InMed Pharmaceuticals has reported Accumulated Expenses over the past 5 years, most recently at $65869.0 for Q4 2025.

  • For Q4 2025, Accumulated Expenses fell 80.47% year-over-year to $65869.0; the TTM value through Dec 2025 reached $65869.0, down 80.47%, while the annual FY2025 figure was $73143.0, 69.78% down from the prior year.
  • Accumulated Expenses for Q4 2025 was $65869.0 at InMed Pharmaceuticals, down from $111662.0 in the prior quarter.
  • Over five years, Accumulated Expenses peaked at $542305.0 in Q2 2023 and troughed at $54629.0 in Q1 2024.
  • A 5-year average of $206735.8 and a median of $138336.0 in 2021 define the central range for Accumulated Expenses.
  • On a YoY basis, Accumulated Expenses climbed as much as 750.58% in 2025 and fell as far as 80.47% in 2025.
  • Year by year, Accumulated Expenses stood at $382114.0 in 2021, then crashed by 63.59% to $139120.0 in 2022, then decreased by 27.8% to $100446.0 in 2023, then soared by 235.74% to $337236.0 in 2024, then tumbled by 80.47% to $65869.0 in 2025.
  • Business Quant data shows Accumulated Expenses for INM at $65869.0 in Q4 2025, $111662.0 in Q3 2025, and $73143.0 in Q2 2025.